{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,16]],"date-time":"2026-10-16T19:58:31Z","timestamp":1792180711008,"version":"4.4.0"},"reference-count":55,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,3,23]],"date-time":"2026-03-23T00:00:00Z","timestamp":1774224000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,3,23]],"date-time":"2026-03-23T00:00:00Z","timestamp":1774224000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["22177124 and 82322063"],"award-info":[{"award-number":["22177124 and 82322063"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["22177124 and 82322063"],"award-info":[{"award-number":["22177124 and 82322063"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sig Transduct Target Ther"],"DOI":"10.1038\/s41392-026-02637-0","type":"journal-article","created":{"date-parts":[[2026,3,23]],"date-time":"2026-03-23T13:43:55Z","timestamp":1774273435000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Potent and selective LSD1 inhibitor DC551040 reveals a promising combination therapy for AML with insight into epigenetic dysregulation"],"prefix":"10.1038","volume":"11","author":[{"given":"Jiang","family":"Wang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0443-4378","authenticated-orcid":false,"given":"Hanlin","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Runhua","family":"Du","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chunpu","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mingbo","family":"Su","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shuni","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Weijuan","family":"Kan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guobin","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yu","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaobei","family":"Hu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Feng","family":"Gao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gaoya","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cong","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wei","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yunfei","family":"Ye","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Li","family":"Sheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuqiang","family":"Shi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yingying","family":"Shao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiangzhou","family":"Song","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuxian","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bo","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0694-3697","authenticated-orcid":false,"given":"Yubo","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6998-8131","authenticated-orcid":false,"given":"He","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3224-001X","authenticated-orcid":false,"given":"Jia","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3685-6268","authenticated-orcid":false,"given":"Hong","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,3,23]]},"reference":[{"key":"2637_CR1","doi-asserted-by":"publisher","first-page":"105","DOI":"10.1038\/nature06092","volume":"449","author":"J Huang","year":"2007","unstructured":"Huang, J. et al. p53 is regulated by the lysine demethylase LSD1. Nature 449, 105\u2013108 (2007).","journal-title":"Nature"},{"key":"2637_CR2","doi-asserted-by":"publisher","DOI":"10.1590\/1414-431x20209230","volume":"53","author":"J Chen","year":"2020","unstructured":"Chen, J. et al. Knocking down LSD1 inhibits the stemness features of colorectal cancer stem cells. Braz. J. Med. Biol. Res. 53, e9230 (2020).","journal-title":"Braz. J. Med. Biol. Res."},{"key":"2637_CR3","first-page":"743","volume":"97","author":"J Ding","year":"2017","unstructured":"Ding, J. et al. The influence and mechanisms of lysine-specific demethylase 1 (LSD1) on invasion and metastasis of colon cancer cells. Zhonghua Yi Xue Za Zhi 97, 743\u2013748 (2017).","journal-title":"Zhonghua Yi Xue Za Zhi"},{"key":"2637_CR4","doi-asserted-by":"publisher","first-page":"235","DOI":"10.1158\/0008-5472.CAN-12-1739","volume":"73","author":"G Ferrari-Amorotti","year":"2013","unstructured":"Ferrari-Amorotti, G. et al. Inhibiting interactions of lysine demethylase LSD1 with snail\/slug blocks cancer cell invasion. Cancer Res. 73, 235\u2013245 (2013).","journal-title":"Cancer Res."},{"key":"2637_CR5","doi-asserted-by":"publisher","first-page":"e35065","DOI":"10.1371\/journal.pone.0035065","volume":"7","author":"T Lv","year":"2012","unstructured":"Lv, T. et al. Over-expression of LSD1 promotes proliferation, migration and invasion in non-small cell lung cancer. PLoS ONE 7, e35065 (2012).","journal-title":"PLoS ONE"},{"key":"2637_CR6","doi-asserted-by":"publisher","first-page":"574","DOI":"10.1002\/ijc.25349","volume":"128","author":"S Hayami","year":"2011","unstructured":"Hayami, S. et al. Overexpression of LSD1 contributes to human carcinogenesis through chromatin regulation in various cancers. Int. J. Cancer 128, 574\u2013586 (2011).","journal-title":"Int. J. Cancer"},{"key":"2637_CR7","doi-asserted-by":"publisher","first-page":"1585","DOI":"10.3390\/cancers11101585","volume":"11","author":"J Verigos","year":"2019","unstructured":"Verigos, J. et al. The histone demethylase LSD1\/KappaDM1A mediates chemoresistance in breast cancer via regulation of a stem cell program. Cancers (Basel) 11, 1585 (2019).","journal-title":"Cancers (Basel)"},{"key":"2637_CR8","doi-asserted-by":"publisher","first-page":"5512524","DOI":"10.1155\/2021\/5512524","volume":"2021","author":"C Agboyibor","year":"2021","unstructured":"Agboyibor, C. et al. LSD1 as a biomarker and the outcome of its inhibitors in the clinical trial: the therapy opportunity in tumor. J. Oncol. 2021, 5512524 (2021).","journal-title":"J. Oncol."},{"key":"2637_CR9","doi-asserted-by":"publisher","first-page":"473","DOI":"10.1016\/j.ccr.2012.03.014","volume":"21","author":"WJ Harris","year":"2012","unstructured":"Harris, W. J. et al. The histone demethylase KDM1A sustains the oncogenic potential of MLL-AF9 leukemia stem cells. Cancer Cell 21, 473\u2013487 (2012).","journal-title":"Cancer Cell"},{"key":"2637_CR10","doi-asserted-by":"publisher","first-page":"451","DOI":"10.1016\/j.ccr.2012.03.027","volume":"21","author":"AA Lokken","year":"2012","unstructured":"Lokken, A. A. & Zeleznik-Le, N. J. Breaking the LSD1\/KDM1A addiction: therapeutic targeting of the epigenetic modifier in AML. Cancer Cell 21, 451\u2013453 (2012).","journal-title":"Cancer Cell"},{"key":"2637_CR11","doi-asserted-by":"publisher","first-page":"4260","DOI":"10.1200\/JCO.19.03250","volume":"38","author":"O Salamero","year":"2020","unstructured":"Salamero, O. et al. First-in-human phase I study of Iadademstat (ORY-1001): a first-in-class lysine-specific histone demethylase 1A inhibitor, in relapsed or refractory acute myeloid leukemia. J. Clin. Oncol. 38, 4260\u20134273 (2020).","journal-title":"J. Clin. Oncol."},{"key":"2637_CR12","doi-asserted-by":"publisher","first-page":"432","DOI":"10.1038\/nature04021","volume":"437","author":"MG Lee","year":"2005","unstructured":"Lee, M. G., Wynder, C., Cooch, N. & Shiekhattar, R. An essential role for CoREST in nucleosomal histone 3 lysine 4 demethylation. Nature 437, 432\u2013435 (2005).","journal-title":"Nature"},{"key":"2637_CR13","doi-asserted-by":"publisher","first-page":"436","DOI":"10.1038\/nature04020","volume":"437","author":"E Metzger","year":"2005","unstructured":"Metzger, E. et al. LSD1 demethylates repressive histone marks to promote androgen-receptor-dependent transcription. Nature 437, 436\u2013439 (2005).","journal-title":"Nature"},{"key":"2637_CR14","doi-asserted-by":"publisher","first-page":"882","DOI":"10.1038\/nature05671","volume":"446","author":"J Wang","year":"2007","unstructured":"Wang, J. et al. Opposing LSD1 complexes function in developmental gene activation and repression programmes. Nature 446, 882\u2013887 (2007).","journal-title":"Nature"},{"key":"2637_CR15","doi-asserted-by":"publisher","first-page":"701","DOI":"10.1038\/s41375-020-0892-z","volume":"35","author":"M Wass","year":"2021","unstructured":"Wass, M. et al. A proof of concept phase I\/II pilot trial of LSD1 inhibition by tranylcypromine combined with ATRA in refractory\/relapsed AML patients not eligible for intensive therapy. Leukemia 35, 701\u2013711 (2021).","journal-title":"Leukemia"},{"key":"2637_CR16","doi-asserted-by":"publisher","first-page":"3376","DOI":"10.1182\/blood-2021-152183","volume":"138","author":"O Salamero","year":"2021","unstructured":"Salamero, O. et al. Iadademstat in combination with azacitidine generates robust and long lasting responses in AML patients (ALICE trial). Blood 138, 3376 (2021).","journal-title":"Blood"},{"key":"2637_CR17","doi-asserted-by":"publisher","first-page":"273","DOI":"10.1158\/1535-7163.MCT-16-0471","volume":"16","author":"Y Ishikawa","year":"2017","unstructured":"Ishikawa, Y. et al. A novel LSD1 inhibitor T-3775440 disrupts GFI1B-containing complex leading to transdifferentiation and impaired growth of AML cells. Mol. Cancer Ther. 16, 273\u2013284 (2017).","journal-title":"Mol. Cancer Ther."},{"key":"2637_CR18","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1158\/2159-8290.CD-21-1059","volume":"12","author":"D Hanahan","year":"2022","unstructured":"Hanahan, D. Hallmarks of cancer: new dimensions. Cancer Discov. 12, 31\u201346 (2022).","journal-title":"Cancer Discov."},{"key":"2637_CR19","doi-asserted-by":"publisher","DOI":"10.1038\/srep08477","volume":"5","author":"W Cao","year":"2015","unstructured":"Cao, W. et al. Homoharringtonine induces apoptosis and inhibits STAT3 via IL-6\/JAK1\/STAT3 signal pathway in Gefitinib-resistant lung cancer cells. Sci. Rep. 5, 8477 (2015).","journal-title":"Sci. Rep."},{"key":"2637_CR20","doi-asserted-by":"publisher","first-page":"330","DOI":"10.1002\/jcp.21066","volume":"212","author":"L Sigalotti","year":"2007","unstructured":"Sigalotti, L. et al. Epigenetic drugs as pleiotropic agents in cancer treatment: biomolecular aspects and clinical applications. J. Cell. Physiol. 212, 330\u2013344 (2007).","journal-title":"J. Cell. Physiol."},{"key":"2637_CR21","doi-asserted-by":"publisher","first-page":"941","DOI":"10.1016\/j.cell.2004.12.012","volume":"119","author":"Y Shi","year":"2004","unstructured":"Shi, Y. et al. Histone demethylation mediated by the nuclear amine oxidase homolog LSD1. Cell 119, 941\u2013953 (2004).","journal-title":"Cell"},{"key":"2637_CR22","doi-asserted-by":"publisher","first-page":"1821","DOI":"10.3390\/cancers11121821","volume":"11","author":"P Karakaidos","year":"2019","unstructured":"Karakaidos, P., Verigos, J. & Magklara, A. LSD1\/KDM1A, a gate-keeper of cancer stemness and a promising therapeutic target. Cancers 11, 1821 (2019).","journal-title":"Cancers"},{"key":"2637_CR23","doi-asserted-by":"publisher","first-page":"3252","DOI":"10.3390\/cells10113252","volume":"10","author":"C Martinez-Gamero","year":"2021","unstructured":"Martinez-Gamero, C., Malla, S. & Aguilo, F. LSD1: expanding functions in stem cells and differentiation. Cells 10, 3252 (2021).","journal-title":"Cells"},{"key":"2637_CR24","doi-asserted-by":"publisher","first-page":"105958","DOI":"10.1016\/j.phrs.2021.105958","volume":"175","author":"X Zhang","year":"2022","unstructured":"Zhang, X. et al. Therapeutic potential of targeting LSD1\/KDM1A in cancers. Pharmacol. Res. 175, 105958 (2022).","journal-title":"Pharmacol. Res."},{"key":"2637_CR25","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1186\/s12929-021-00737-3","volume":"28","author":"D Kim","year":"2021","unstructured":"Kim, D., Kim, K. I. & Baek, S. H. Roles of lysine-specific demethylase 1 (LSD1) in homeostasis and diseases. J. Biomed. Sci. 28, 41 (2021).","journal-title":"J. Biomed. Sci."},{"key":"2637_CR26","doi-asserted-by":"publisher","first-page":"7017","DOI":"10.1038\/s41388-019-0923-2","volume":"38","author":"X Hu","year":"2019","unstructured":"Hu, X. et al. LSD1 suppresses invasion, migration and metastasis of luminal breast cancer cells via activation of GATA3 and repression of TRIM37 expression. Oncogene 38, 7017\u20137034 (2019).","journal-title":"Oncogene"},{"key":"2637_CR27","first-page":"2030","volume":"8","author":"R Qiu","year":"2018","unstructured":"Qiu, R. et al. BRMS1 coordinates with LSD1 and suppresses breast cancer cell metastasis. Am. J. Cancer Res. 8, 2030\u20132045 (2018).","journal-title":"Am. J. Cancer Res."},{"key":"2637_CR28","doi-asserted-by":"publisher","first-page":"245","DOI":"10.1016\/j.drup.2004.06.004","volume":"7","author":"MA Alaoui-Jamali","year":"2004","unstructured":"Alaoui-Jamali, M. A., Dupre, I. & Qiang, H. Prediction of drug sensitivity and drug resistance in cancer by transcriptional and proteomic profiling. Drug Resist. Updat. 7, 245\u2013255 (2004).","journal-title":"Drug Resist. Updat."},{"key":"2637_CR29","doi-asserted-by":"publisher","first-page":"299","DOI":"10.1038\/s41586-019-1730-1","volume":"575","author":"N Vasan","year":"2019","unstructured":"Vasan, N., Baselga, J. & Hyman, D. M. A view on drug resistance in cancer. Nature 575, 299\u2013309 (2019).","journal-title":"Nature"},{"key":"2637_CR30","doi-asserted-by":"publisher","first-page":"637","DOI":"10.1038\/s41573-022-00409-3","volume":"21","author":"F Meissner","year":"2022","unstructured":"Meissner, F., Geddes-McAlister, J., Mann, M. & Bantscheff, M. The emerging role of mass spectrometry-based proteomics in drug discovery. Nat. Rev. Drug Discov. 21, 637\u2013654 (2022).","journal-title":"Nat. Rev. Drug Discov."},{"key":"2637_CR31","doi-asserted-by":"publisher","first-page":"1037","DOI":"10.1016\/j.celrep.2014.07.010","volume":"8","author":"ML Sos","year":"2014","unstructured":"Sos, M. L. et al. Oncogene mimicry as a mechanism of primary resistance to BRAF inhibitors. Cell Rep. 8, 1037\u20131048 (2014).","journal-title":"Cell Rep."},{"key":"2637_CR32","doi-asserted-by":"publisher","first-page":"307","DOI":"10.1016\/j.cell.2012.02.053","volume":"149","author":"JS Duncan","year":"2012","unstructured":"Duncan, J. S. et al. Dynamic reprogramming of the kinome in response to targeted MEK inhibition in triple-negative breast cancer. Cell 149, 307\u2013321 (2012).","journal-title":"Cell"},{"key":"2637_CR33","doi-asserted-by":"publisher","first-page":"2617","DOI":"10.1021\/acs.jproteome.5b00161","volume":"14","author":"H Koch","year":"2015","unstructured":"Koch, H., Busto, M. E., Kramer, K., Medard, G. & Kuster, B. Chemical proteomics uncovers EPHA2 as a mechanism of acquired resistance to small molecule EGFR kinase inhibition. J. Proteome Res. 14, 2617\u20132625 (2015).","journal-title":"J. Proteome Res."},{"key":"2637_CR34","doi-asserted-by":"publisher","first-page":"1324","DOI":"10.1126\/science.aah6893","volume":"355","author":"E Toska","year":"2017","unstructured":"Toska, E. et al. PI3K pathway regulates ER-dependent transcription in breast cancer through the epigenetic regulator KMT2D. Science 355, 1324\u20131330 (2017).","journal-title":"Science"},{"key":"2637_CR35","doi-asserted-by":"publisher","first-page":"665","DOI":"10.1016\/j.bbrc.2012.04.057","volume":"421","author":"A Janzer","year":"2012","unstructured":"Janzer, A. et al. Lysine-specific demethylase 1 (LSD1) and histone deacetylase 1 (HDAC1) synergistically repress proinflammatory cytokines and classical complement pathway components. Biochem. Biophys. Res. Commun. 421, 665\u2013670 (2012).","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"2637_CR36","doi-asserted-by":"publisher","first-page":"549","DOI":"10.1016\/j.cell.2018.05.052","volume":"174","author":"W Sheng","year":"2018","unstructured":"Sheng, W. et al. LSD1 Ablation stimulates anti-tumor immunity and enables checkpoint blockade. Cell 174, 549\u2013563 e19 (2018).","journal-title":"Cell"},{"key":"2637_CR37","doi-asserted-by":"publisher","first-page":"878","DOI":"10.1038\/s41388-021-02123-7","volume":"41","author":"L Nicosia","year":"2022","unstructured":"Nicosia, L. et al. Pharmacological inhibition of LSD1 triggers myeloid differentiation by targeting GSE1 oncogenic functions in AML. Oncogene 41, 878\u2013894 (2022).","journal-title":"Oncogene"},{"key":"2637_CR38","doi-asserted-by":"publisher","first-page":"6854","DOI":"10.1073\/pnas.1700715114","volume":"114","author":"Q Wang","year":"2017","unstructured":"Wang, Q. et al. Host-secreted antimicrobial peptide enforces symbiotic selectivity in Medicago truncatula. Proc. Natl. Acad. Sci. USA 114, 6854\u20136859 (2017).","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"2637_CR39","doi-asserted-by":"publisher","first-page":"1309","DOI":"10.1002\/1878-0261.13124","volume":"16","author":"W Yan","year":"2022","unstructured":"Yan, W. et al. Intrinsic and acquired drug resistance to LSD1 inhibitors in small cell lung cancer occurs through a TEAD4-driven transcriptional state. Mol. Oncol. 16, 1309\u20131328 (2022).","journal-title":"Mol. Oncol."},{"key":"2637_CR40","doi-asserted-by":"publisher","first-page":"682","DOI":"10.1038\/nchembio.118","volume":"4","author":"AL Hopkins","year":"2008","unstructured":"Hopkins, A. L. Network pharmacology: the next paradigm in drug discovery. Nat. Chem. Biol. 4, 682\u2013690 (2008).","journal-title":"Nat. Chem. Biol."},{"key":"2637_CR41","doi-asserted-by":"publisher","first-page":"645","DOI":"10.1038\/448645a","volume":"448","author":"CR Chong","year":"2007","unstructured":"Chong, C. R. & Sullivan, D. J. Jr. New uses for old drugs. Nature 448, 645\u2013646 (2007).","journal-title":"Nature"},{"key":"2637_CR42","doi-asserted-by":"publisher","first-page":"1929","DOI":"10.1126\/science.1132939","volume":"313","author":"J Lamb","year":"2006","unstructured":"Lamb, J. et al. The Connectivity Map: using gene-expression signatures to connect small molecules, genes, and disease. Science 313, 1929\u20131935 (2006).","journal-title":"Science"},{"key":"2637_CR43","doi-asserted-by":"publisher","first-page":"1437","DOI":"10.1016\/j.cell.2017.10.049","volume":"171","author":"A Subramanian","year":"2017","unstructured":"Subramanian, A. et al. A next generation connectivity map: L1000 platform and the first 1,000,000 profiles. Cell 171, 1437\u20131452 e17 (2017).","journal-title":"Cell"},{"key":"2637_CR44","doi-asserted-by":"publisher","first-page":"12940","DOI":"10.1080\/21655979.2021.2012626","volume":"12","author":"M Qu","year":"2021","unstructured":"Qu, M., Li, J. & Yuan, L. Uncovering the action mechanism of homoharringtonine against colorectal cancer by using network pharmacology and experimental evaluation. Bioengineered 12, 12940\u201312953 (2021).","journal-title":"Bioengineered"},{"key":"2637_CR45","doi-asserted-by":"publisher","first-page":"114538","DOI":"10.1016\/j.bcp.2021.114538","volume":"188","author":"F Wang","year":"2021","unstructured":"Wang, F. et al. Homoharringtonine synergizes with quizartinib in FLT3-ITD acute myeloid leukemia by targeting FLT3-AKT-c-Myc pathway. Biochem. Pharmacol. 188, 114538 (2021).","journal-title":"Biochem. Pharmacol."},{"key":"2637_CR46","doi-asserted-by":"publisher","first-page":"2220","DOI":"10.1073\/pnas.1818539116","volume":"116","author":"XJ Chen","year":"2019","unstructured":"Chen, X. J. et al. Homoharringtonine deregulates MYC transcriptional expression by directly binding NF-kappaB repressing factor. Proc. Natl. Acad. Sci. USA 116, 2220\u20132225 (2019).","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"2637_CR47","doi-asserted-by":"publisher","first-page":"259","DOI":"10.1111\/j.1600-0609.2008.01116.x","volume":"81","author":"H Tong","year":"2008","unstructured":"Tong, H., Ren, Y., Zhang, F. & Jin, J. Homoharringtonine affects the JAK2-STAT5 signal pathway through alteration of protein tyrosine kinase phosphorylation in acute myeloid leukemia cells. Eur. J. Haematol. 81, 259\u2013266 (2008).","journal-title":"Eur. J. Haematol."},{"key":"2637_CR48","doi-asserted-by":"publisher","first-page":"1040","DOI":"10.1080\/16078454.2021.2009642","volume":"26","author":"F Wang","year":"2021","unstructured":"Wang, F. et al. Low dose of homoharringtonine and cytarabine-based priming induction regimens for patients with de novo acute myeloid leukemia and high-risk myelodysplastic syndrome aged over 70 years. Hematology 26, 1040\u20131045 (2021).","journal-title":"Hematology"},{"key":"2637_CR49","doi-asserted-by":"publisher","first-page":"359ra129","DOI":"10.1126\/scitranslmed.aaf3735","volume":"8","author":"SS Lam","year":"2016","unstructured":"Lam, S. S. et al. Homoharringtonine (omacetaxine mepesuccinate) as an adjunct for FLT3-ITD acute myeloid leukemia. Sci. Transl. Med. 8, 359ra129 (2016).","journal-title":"Sci. Transl. Med."},{"key":"2637_CR50","doi-asserted-by":"publisher","first-page":"3791","DOI":"10.1182\/blood-2014-06-584656","volume":"124","author":"E Bibikova","year":"2014","unstructured":"Bibikova, E. et al. TNF-mediated inflammation represses GATA1 and activates p38 MAP kinase in RPS19-deficient hematopoietic progenitors. Blood 124, 3791\u20133798 (2014).","journal-title":"Blood"},{"key":"2637_CR51","doi-asserted-by":"publisher","first-page":"379","DOI":"10.1007\/s00262-009-0756-x","volume":"59","author":"N Hardwick","year":"2010","unstructured":"Hardwick, N., Chan, L., Ingram, W., Mufti, G. & Farzaneh, F. Lytic activity against primary AML cells is stimulated in vitro by an autologous whole cell vaccine expressing IL-2 and CD80. Cancer immunol. Immunother. 59, 379\u2013388 (2010).","journal-title":"Cancer immunol. Immunother."},{"key":"2637_CR52","doi-asserted-by":"publisher","first-page":"267","DOI":"10.1034\/j.1600-0609.2001.0430a.x","volume":"67","author":"B Foss","year":"2001","unstructured":"Foss, B., Ulvestad, E. & Bruserud, \u00d8 Platelet-derived growth factor (PDGF) in human acute myelogenous leukemia: PDGF receptor expression, endogenous PDGF release and responsiveness to exogenous PDGF isoforms by in vitro cultured acute myelogenous leukemia blasts. Eur. J. Haematol. 67, 267\u2013278 (2001).","journal-title":"Eur. J. Haematol."},{"key":"2637_CR53","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.aaw8828","volume":"11","author":"K Melgar","year":"2019","unstructured":"Melgar, K. et al. Overcoming adaptive therapy resistance in AML by targeting immune response pathways. Sci. Transl. Med. 11, eaaw8828 (2019).","journal-title":"Sci. Transl. Med."},{"key":"2637_CR54","doi-asserted-by":"publisher","first-page":"504","DOI":"10.1016\/j.csbj.2015.09.001","volume":"13","author":"B Yadav","year":"2015","unstructured":"Yadav, B., Wennerberg, K., Aittokallio, T. & Tang, J. Searching for drug synergy in complex dose\u2013response landscapes using an interaction potency model. Comput. Struct. Biotechnol. J. 13, 504\u2013513 (2015).","journal-title":"Comput. Struct. Biotechnol. J."},{"key":"2637_CR55","doi-asserted-by":"publisher","first-page":"W488","DOI":"10.1093\/nar\/gkaa216","volume":"48","author":"A Ianevski","year":"2020","unstructured":"Ianevski, A., Giri, A. K. & Aittokallio, T. SynergyFinder 2.0: visual analytics of multi-drug combination synergies. Nucleic Acids Res. 48, W488\u2013W493 (2020).","journal-title":"Nucleic Acids Res."}],"container-title":["Signal Transduction and Targeted Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41392-026-02637-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41392-026-02637-0","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41392-026-02637-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,24]],"date-time":"2026-03-24T06:04:17Z","timestamp":1774332257000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41392-026-02637-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3,23]]},"references-count":55,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["2637"],"URL":"https:\/\/doi.org\/10.1038\/s41392-026-02637-0","relation":{},"ISSN":["2059-3635"],"issn-type":[{"value":"2059-3635","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,3,23]]},"assertion":[{"value":"24 December 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 January 2026","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 February 2026","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 March 2026","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"108"}}